Molecular Dynamics Studies on HIV-1 Protease: Drug Resistance and Folding Pathways [PDF]
, 2001 Drug resistance to HIV-1 Protease involves accumulation of multiple mutations in the protein. Here we investigate the role of these mutations by using molecular dynamics simulations which exploit the influence of the native-state topology in the folding ...
Carloni, Paolo +3 more
core +2 more sources
Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay. [PDF]
, 2011 Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide.
Agudelo, Juliet +10 more
core +1 more source
Töltéssel rendelkező oldalláncok szerepe retrovirális proteinázok szubsztrát-specificitásában = Role of the charged residues on the substrate specificity of retroviral proteinases [PDF]
, 2006 A HIV-1 életciklusában betöltött szerepe miatt terápiás (AIDS) célponttá vált retrovirális proteáz (PR) vizsgálatával betekintést nyerhetünk az enzim inhibitorokkal szembeni rezisztencia kialakulásának molekuláris mechanizmusáról.
Boross, Péter, Fehér, Anita
core
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]
, 2015 One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A. +2 more
core +2 more sources
AIDS Research and Therapy, 2010 Background HIV protease (PR) is a virus-encoded aspartic protease that is essential for viral replication and infectivity. The fully active and mature dimeric protease is released from the Gag-Pol polyprotein as a result of precursor autoprocessing ...
Chen Chaoping, Huang Liangqun
doaj +1 more source
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. [PDF]
PLoS ONE, 2013 Use of antiretroviral-based microbicides for HIV-1 prophylaxis could introduce a transmission barrier that inadvertently facilitates the selection of fitter viral variants among incident infections.
Denis R Chopera +15 more
doaj +1 more source
Proteochemometric modeling of HIV protease susceptibility
BMC Bioinformatics, 2008 Background A major obstacle in treatment of HIV is the ability of the virus to mutate rapidly into drug-resistant variants. A method for predicting the susceptibility of mutated HIV strains to antiviral agents would provide substantial clinical benefit ...
Prusis Peteris +4 more
doaj +1 more source
PLoS ONE, 2015 ObjectiveLimited data are available from the developing world on antiretroviral drug resistance in HIV-1 infected children failing protease inhibitor-based antiretroviral therapy, especially in the context of a high tuberculosis burden.
Theresa M Rossouw +6 more
doaj +1 more source
Modulation of the LDL receptor and LRP levels by HIV protease inhibitors
Journal of Lipid Research, 2003 Inhibitors of the human immunodeficiency virus (HIV)-1 protease have proven to be effective antiretroviral drugs. However, patients receiving these drugs develop serious metabolic abnormalities, including hypercholesterolemia.
Huan Tran +3 more
doaj +1 more source
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor ntiretroviral regimens failed [PDF]
, 2004 The association between minor mutations in human immunodeficiency virus (HIV) protease at baseline and development of common primary mutation 90M at virological failure (conferring some resistance to all protease inhibitors [PIs]) was evaluated in 93
Antonella, D'Arminio Monforte +11 more
core